BioCentury
ARTICLE | Company News

Ribapharm down on patent ruling

July 16, 2003 7:00 AM UTC

RNA was off $1.37 (20%) to $5.47 on 4.8 million shares on Wednesday. The company said the U.S. District Court for the Central District of California granted summary judgment of non-infringement in RNA and ICN's ribavirin patent infringement suit against Geneva Pharmaceuticals, Teva (TEVA) and Three Rivers (Cranberry Township, Penn.). Geneva is a subsidiary of Novartis (NVS; SWX:NOVN). RNA and ICN, which holds a majority stake in RNA, said they plan to appeal the ruling. ...